Drug Profile
Tizanidine implant - Braeburn Pharmaceuticals
Alternative Names: BB 1216Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Braeburn Pharmaceuticals
- Class Antispastics; Benzothiazoles; Imidazolines; Muscle relaxants; Small molecules
- Mechanism of Action Alpha 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Muscle spasticity
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for phase-I development in Muscle-spasticity in Unknown (Implant)
- 09 Feb 2017 Chemical structure information added
- 11 Jan 2017 Phase-I clinical trials in Muscle spasticity (unspecified route)